Corline Biomedical AB reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 35.52 million compared to SEK 32.59 million a year ago. Revenue was SEK 35.93 million compared to SEK 33.33 million a year ago.

Net loss was SEK 1.81 million compared to net income of SEK 2.33 million a year ago. Basic loss per share from continuing operations was SEK 0.08 compared to basic earnings per share from continuing operations of SEK 0.11 a year ago. Diluted loss per share from continuing operations was SEK 0.08 compared to diluted earnings per share from continuing operations of SEK 0.11 a year ago.